{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:06:34Z","timestamp":1792533994984,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>The treatment of inflammatory bowel disease (IBD) has evolved significantly over time based on \u201ctreat-to-target\u201d, an approach which uses sequential objective makers to monitor response to therapy with the ultimate goal of achieving endoscopic healing. Biomarkers, including C-reactive protein and fecal calprotectin, are an important noninvasive intermediate step in this treatment approach as well as in routine monitoring of disease activity. While widely utilized, there is significant variability and some uncertainty in biomarker implementation; this review summarizes evidence for the use of biomarkers in IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) update in combination with the 2023 American Gastroenterological Association (AGA) guidelines on the role of biomarkers in the management of both Crohn\u2019s disease and ulcerative colitis have offered significant new guidance for those who manage IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Biomarkers offer important insight into disease activity and can be used to track progress toward deeper levels of remission in IBD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11894-025-00991-7","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:35:12Z","timestamp":1750394112000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Applying Biomarkers in Treat-to-target Approach for IBD"],"prefix":"10.1007","volume":"27","author":[{"given":"Megan","family":"Lutz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy","family":"Caldera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"issue":"4","key":"991_CR1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/ajg.2016.59","volume":"111","author":"DJ Gracie","year":"2016","unstructured":"Gracie DJ, Williams CJM, Sood R, et al. Poor correlation between clinical disease activity and mucosal inflammation, and the role of psychological comorbidity, in inflammatory bowel disease. Am J Gastroenterol. 2016;111(4):541\u201351. https:\/\/doi.org\/10.1038\/ajg.2016.59.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"991_CR2","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324\u201338. https:\/\/doi.org\/10.1038\/ajg.2015.233.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"991_CR3","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570\u201383. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031.","journal-title":"Gastroenterology"},{"issue":"9","key":"991_CR4","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ibd.20927","volume":"15","author":"F Schnitzler","year":"2009","unstructured":"Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn\u02bcs disease. Inflamm Bowel Dis. 2009;15(9):1295\u2013301. https:\/\/doi.org\/10.1002\/ibd.20927.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"991_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/j.gastro.2009.09.056","volume":"138","author":"F Baert","year":"2010","unstructured":"Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn\u2019s disease. Gastroenterology. 2010;138(2):463\u20138. https:\/\/doi.org\/10.1053\/j.gastro.2009.09.056.","journal-title":"Gastroenterology"},{"issue":"11","key":"991_CR6","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1136\/gutjnl-2012-302830","volume":"61","author":"MF Neurath","year":"2012","unstructured":"Neurath MF, Travis SPL. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61(11):1619\u201335. https:\/\/doi.org\/10.1136\/gutjnl-2012-302830.","journal-title":"Gut"},{"issue":"2","key":"991_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1053\/j.gastro.2007.05.051","volume":"133","author":"KF Fr\u00f8slie","year":"2007","unstructured":"Fr\u00f8slie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort. Gastroenterology. 2007;133(2):412\u201322. https:\/\/doi.org\/10.1053\/j.gastro.2007.05.051.","journal-title":"Gastroenterology"},{"issue":"10114","key":"991_CR8","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","volume":"390","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial. The Lancet. 2017;390(10114):2779\u201389. https:\/\/doi.org\/10.1016\/S0140-6736(17)32641-7.","journal-title":"The Lancet"},{"issue":"11","key":"991_CR9","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.cgh.2008.06.010","volume":"6","author":"J Jones","year":"2008","unstructured":"Jones J, Loftus EV, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2008;6(11):1218\u201324. https:\/\/doi.org\/10.1016\/j.cgh.2008.06.010.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"991_CR10","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1053\/j.gastro.2021.05.063","volume":"161","author":"SK Murthy","year":"2021","unstructured":"Murthy SK, Feuerstein JD, Nguyen GC, Velayos FS. AGA clinical practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: Expert review. Gastroenterology. 2021;161(3):1043-1051.e4. https:\/\/doi.org\/10.1053\/j.gastro.2021.05.063.","journal-title":"Gastroenterology"},{"issue":"3","key":"991_CR11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.gastro.2022.12.007","volume":"164","author":"S Singh","year":"2023","unstructured":"Singh S, Ananthakrishnan AN, Nguyen NH, et al. AGA clinical practice guideline on the role of biomarkers for the management of ulcerative colitis. Gastroenterology. 2023;164(3):344\u201372. https:\/\/doi.org\/10.1053\/j.gastro.2022.12.007.","journal-title":"Gastroenterology"},{"issue":"6","key":"991_CR12","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1053\/j.gastro.2023.09.029","volume":"165","author":"AN Ananthakrishnan","year":"2023","unstructured":"Ananthakrishnan AN, Adler J, Chachu KA, et al. AGA clinical practice guideline on the role of biomarkers for the management of Crohn\u2019s disease. Gastroenterology. 2023;165(6):1367\u201399. https:\/\/doi.org\/10.1053\/j.gastro.2023.09.029.","journal-title":"Gastroenterology"},{"key":"991_CR13","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.1016\/S0399-8320(09)73151-3","volume":"33","author":"JL Mendoza","year":"2009","unstructured":"Mendoza JL, Abreu MT. Biological markers in inflammatory bowel disease: Practical consideration for clinicians. Gastroenterol Clin Biol. 2009;33:S158\u201373. https:\/\/doi.org\/10.1016\/S0399-8320(09)73151-3.","journal-title":"Gastroenterol Clin Biol"},{"issue":"19","key":"991_CR14","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.3748\/wjg.v25.i19.2354","volume":"25","author":"E Sollelis","year":"2019","unstructured":"Sollelis E, Quinard RM, Bouguen G, et al. Combined evaluation of biomarkers as predictor of maintained remission in Crohn\u2019s disease. World J Gastroenterol. 2019;25(19):2354\u201364. https:\/\/doi.org\/10.3748\/wjg.v25.i19.2354.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"991_CR15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10620-013-2907-3","volume":"59","author":"JY Yoon","year":"2014","unstructured":"Yoon JY, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci. 2014;59(4):829\u201337. https:\/\/doi.org\/10.1007\/s10620-013-2907-3.","journal-title":"Dig Dis Sci."},{"issue":"8","key":"991_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/01.MIB.0000173271.18319.53","volume":"11","author":"CA Solem","year":"2005","unstructured":"Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-Reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11(8):707\u201312. https:\/\/doi.org\/10.1097\/01.MIB.0000173271.18319.53.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"991_CR17","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1093\/ibd\/izy100","volume":"24","author":"CJ Moran","year":"2018","unstructured":"Moran CJ, Kaplan JL, Winter HS. Genetic variation affects C-Reactive protein elevations in Crohn\u2019s disease. Inflamm Bowel Dis. 2018;24(9):2048\u201352. https:\/\/doi.org\/10.1093\/ibd\/izy100.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"991_CR18","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ajg.2015.120","volume":"110","author":"MH Mosli","year":"2015","unstructured":"Mosli MH, Zou G, Garg SK, et al. C-Reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: A systematic review and meta-analysis. Am J Gastroenterol. 2015;110(6):802\u201319. https:\/\/doi.org\/10.1038\/ajg.2015.120.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"991_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.15403\/jgld.2014.1121.273.pti","volume":"27","author":"T Rokkas","year":"2018","unstructured":"Rokkas T, Portincasa P, Koutroubakis IE. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis. J Gastrointestin Liver Dis. 2018;27(3):299\u2013306. https:\/\/doi.org\/10.15403\/jgld.2014.1121.273.pti.","journal-title":"J Gastrointestin Liver Dis."},{"issue":"3","key":"991_CR20","first-page":"77","volume":"39","author":"WGW Pathirana","year":"2018","unstructured":"Pathirana WGW, Chubb SP, Gillett MJ, Vasikaran SD. Faecal calprotectin. Clin Biochem Rev. 2018;39(3):77\u201390.","journal-title":"Clin Biochem Rev"},{"issue":"4","key":"991_CR21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/j.1572-0241.2007.01126.x","volume":"102","author":"AC von Roon","year":"2007","unstructured":"von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102(4):803\u201313. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01126.x.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"991_CR22","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41395-018-0211-8","volume":"113","author":"JE Axelrad","year":"2018","unstructured":"Axelrad JE, Joelson A, Green PHR, et al. Enteric infections are common in patients with flares of inflammatory bowel disease. Am J Gastroenterol. 2018;113(10):1530\u20139. https:\/\/doi.org\/10.1038\/s41395-018-0211-8.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"991_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/ueg2.12069","volume":"9","author":"F D\u2019Amico","year":"2021","unstructured":"D\u2019Amico F, Rubin DT, Kotze PG, et al. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United Eur Gastroenterol J. 2021;9(4):451\u201360. https:\/\/doi.org\/10.1002\/ueg2.12069.","journal-title":"United Eur Gastroenterol J"},{"issue":"5","key":"991_CR24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3109\/00365521.2015.1117650","volume":"51","author":"V Kristensen","year":"2016","unstructured":"Kristensen V, Malmstr\u00f8m GH, Skar V, R\u00f8seth A, Moum B. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure. Scand J Gastroenterol. 2016;51(5):548\u201355. https:\/\/doi.org\/10.3109\/00365521.2015.1117650.","journal-title":"Scand J Gastroenterol"},{"key":"991_CR25","doi-asserted-by":"publisher","unstructured":"Lasson A, Stotzer PO, \u00d6hman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: A prospective study in patients with active ulcerative colitis. J Crohns Colitis. Published online July 2014. https:\/\/doi.org\/10.1016\/j.crohns.2014.06.002.","DOI":"10.1016\/j.crohns.2014.06.002"},{"issue":"9","key":"991_CR26","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1097\/MIB.0000000000001157","volume":"23","author":"A Patel","year":"2017","unstructured":"Patel A, Panchal H, Dubinsky MC. Fecal calprotectin levels predict histological healing in ulcerative colitis. Inflamm Bowel Dis. 2017;23(9):1600\u20134. https:\/\/doi.org\/10.1097\/MIB.0000000000001157.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"991_CR27","doi-asserted-by":"publisher","first-page":"otab028","DOI":"10.1093\/crocol\/otab028","volume":"3","author":"NS Khakoo","year":"2021","unstructured":"Khakoo NS, Lewis A, Roldan GA, et al. Patient adherence to fecal calprotectin testing is low compared to other commonly ordered tests in patients with inflammatory bowel disease. Crohns Colitis 360. 2021;3(3):otab028. https:\/\/doi.org\/10.1093\/crocol\/otab028.","journal-title":"Crohns Colitis 360."},{"issue":"1","key":"991_CR28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1572-0241.2007.01556.x","volume":"103","author":"J Langhorst","year":"2008","unstructured":"Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: Performance of fecal lactoferrin, calprotectin, and PMN-Elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103(1):162\u20139. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01556.x.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"991_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1053\/j.gastro.2020.03.039","volume":"159","author":"RC Ungaro","year":"2020","unstructured":"Ungaro RC, Yzet C, Bossuyt P, et al. Deep remission at 1 year prevents progression of early Crohn\u2019s disease. Gastroenterology. 2020;159(1):139\u201347. https:\/\/doi.org\/10.1053\/j.gastro.2020.03.039.","journal-title":"Gastroenterology"},{"issue":"4","key":"991_CR30","doi-asserted-by":"publisher","first-page":"748","DOI":"10.14309\/ajg.0000000000002122","volume":"118","author":"CS Tse","year":"2023","unstructured":"Tse CS, Singh S, Valasek MA, et al. Prevalence and correlations of gastrointestinal symptoms with endoscopic and histologic mucosal healing in Crohn\u2019s disease. Am J Gastroenterol. 2023;118(4):748\u201351. https:\/\/doi.org\/10.14309\/ajg.0000000000002122.","journal-title":"Am J Gastroenterol."},{"issue":"1","key":"991_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ibd.20312","volume":"14","author":"T Sipponen","year":"2008","unstructured":"Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, F\u00e4rkkil\u00e4 M. Crohn\u02bcs disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn\u02bcs disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14(1):40\u20136. https:\/\/doi.org\/10.1002\/ibd.20312.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"991_CR32","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1002\/ibd.22917","volume":"18","author":"G D\u2019Haens","year":"2012","unstructured":"D\u2019Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218\u201324. https:\/\/doi.org\/10.1002\/ibd.22917.","journal-title":"Inflamm Bowel Dis."},{"issue":"12","key":"991_CR33","doi-asserted-by":"publisher","first-page":"e641","DOI":"10.1016\/j.crohns.2013.05.005","volume":"7","author":"T Lobat\u00f3n","year":"2013","unstructured":"Lobat\u00f3n T, L\u00f3pez-Garc\u00eda A, Rodr\u00edguez-Moranta F, Ruiz A, Rodr\u00edguez L, Guardiola J. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn\u2019s disease. J Crohns Colitis. 2013;7(12):e641\u201351. https:\/\/doi.org\/10.1016\/j.crohns.2013.05.005.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"991_CR34","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/MPG.0000000000002458","volume":"69","author":"SM Haisma","year":"2019","unstructured":"Haisma SM, Verkade HJ, Scheenstra R, van der Doef HPJ, Bodewes FAJA, van Rheenen PF. Time-to-reach target calprotectin level in newly diagnosed patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2019;69(4):466\u201373. https:\/\/doi.org\/10.1097\/MPG.0000000000002458.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"991_CR35","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/MIB.0000000000001082","volume":"23","author":"A Heida","year":"2017","unstructured":"Heida A, Park KT, van Rheenen PF. Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(6):894\u2013902. https:\/\/doi.org\/10.1097\/MIB.0000000000001082.","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"991_CR36","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/ecco-jcc\/jjv061","volume":"9","author":"X Roblin","year":"2015","unstructured":"Roblin X, Marotte H, Leclerc M, et al. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. J Crohns Colitis. 2015;9(7):525\u201331. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv061.","journal-title":"J Crohns Colitis"},{"issue":"9317","key":"991_CR37","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. The Lancet. 2002;359(9317):1541\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(02)08512-4.","journal-title":"The Lancet"},{"issue":"4","key":"991_CR38","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/apt.13276","volume":"42","author":"JP Gisbert","year":"2015","unstructured":"Gisbert JP, Mar\u00edn AC, Chaparro M. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti- TNF therapy. Aliment Pharmacol Ther. 2015;42(4):391\u2013405. https:\/\/doi.org\/10.1111\/apt.13276.","journal-title":"Aliment Pharmacol Ther"},{"key":"991_CR39","doi-asserted-by":"publisher","first-page":"S011","DOI":"10.1093\/ecco-jcc\/jjx180.014","volume":"12","author":"W Reinisch","year":"2018","unstructured":"Reinisch W, Panaccione R, Bossuyt P, et al. Biomarker correlation with endoscopic outcomes in patients with Crohn\u2019s disease: data from CALM. J Crohns Colitis. 2018;12:S011\u2013S011. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx180.014.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"991_CR40","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/gutjnl-2013-304984","volume":"63","author":"L Peyrin-Biroulet","year":"2014","unstructured":"Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn\u2019s disease in the SONIC trial. Gut. 2014;63(1):88\u201395. https:\/\/doi.org\/10.1136\/gutjnl-2013-304984.","journal-title":"Gut"},{"issue":"4","key":"991_CR41","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S2468-1253(21)00474-X","volume":"7","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, D\u2019Haens G, et al. Treat to target versus standard of care for patients with Crohn\u2019s disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterol Hepatol. 2022;7(4):294\u2013306. https:\/\/doi.org\/10.1016\/S2468-1253(21)00474-X.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"991_CR42","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1053\/j.gastro.2016.10.039","volume":"152","author":"M Regueiro","year":"2017","unstructured":"Regueiro M, Velayos F, Greer JB, et al. American gastroenterological association institute technical review on the management of Crohn\u2019s disease after surgical resection. Gastroenterology. 2017;152(1):277-295.e3. https:\/\/doi.org\/10.1053\/j.gastro.2016.10.039.","journal-title":"Gastroenterology"},{"key":"991_CR43","doi-asserted-by":"publisher","first-page":"goac070","DOI":"10.1093\/gastro\/goac070","volume":"10","author":"KE Lee","year":"2022","unstructured":"Lee KE, Cantrell S, Shen B, Faye AS. Post-operative prevention and monitoring of Crohn\u2019s disease recurrence. Gastroenterol Rep (Oxf). 2022;10:goac070. https:\/\/doi.org\/10.1093\/gastro\/goac070.","journal-title":"Gastroenterol Rep (Oxf)."},{"issue":"6","key":"991_CR44","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.cgh.2019.09.040","volume":"18","author":"EL Barnes","year":"2020","unstructured":"Barnes EL, Lightner AL, Regueiro M. Perioperative and postoperative management of patients with Crohn\u2019s disease and ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(6):1356\u201366. https:\/\/doi.org\/10.1016\/j.cgh.2019.09.040.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"991_CR45","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1053\/j.gastro.2015.07.003","volume":"149","author":"BE Sands","year":"2015","unstructured":"Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology. 2015;149(5):1275-1285.e2. https:\/\/doi.org\/10.1053\/j.gastro.2015.07.003.","journal-title":"Gastroenterology"},{"issue":"10","key":"991_CR46","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1097\/MIB.0b013e31829b2a37","volume":"19","author":"VM De","year":"2013","unstructured":"De VM, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013;19(10):2111\u20137. https:\/\/doi.org\/10.1097\/MIB.0b013e31829b2a37.","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"991_CR47","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.dld.2014.07.013","volume":"46","author":"L Guidi","year":"2014","unstructured":"Guidi L, Marzo M, Andrisani G, et al. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor \u03b1 agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. Dig Liver Dis. 2014;46(11):974\u20139. https:\/\/doi.org\/10.1016\/j.dld.2014.07.013.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"991_CR48","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1053\/j.gastro.2020.06.043","volume":"159","author":"H Yoon","year":"2020","unstructured":"Yoon H, Jangi S, Dulai PS, et al. Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: A systematic review and meta-analysis. Gastroenterology. 2020;159(4):1262-1275.e7. https:\/\/doi.org\/10.1053\/j.gastro.2020.06.043.","journal-title":"Gastroenterology"},{"issue":"1","key":"991_CR49","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12876-021-01788-4","volume":"21","author":"A Sakuraba","year":"2021","unstructured":"Sakuraba A, Nemoto N, Hibi N, et al. Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis. BMC Gastroenterol. 2021;21(1):197. https:\/\/doi.org\/10.1186\/s12876-021-01788-4.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"991_CR50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12876-016-0462-z","volume":"16","author":"K Kawashima","year":"2016","unstructured":"Kawashima K, Ishihara S, Yuki T, et al. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol. 2016;16(1):47. https:\/\/doi.org\/10.1186\/s12876-016-0462-z.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"991_CR51","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/apt.15577","volume":"51","author":"PS Dulai","year":"2020","unstructured":"Dulai PS, Singh S, Jairath V, et al. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Aliment Pharmacol Ther. 2020;51(4):435\u201345. https:\/\/doi.org\/10.1111\/apt.15577.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"991_CR52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.gastro.2023.10.015","volume":"166","author":"EL Barnes","year":"2024","unstructured":"Barnes EL, Agrawal M, Syal G, et al. AGA clinical practice guideline on the management of pouchitis and inflammatory pouch disorders. Gastroenterology. 2024;166(1):59\u201385. https:\/\/doi.org\/10.1053\/j.gastro.2023.10.015.","journal-title":"Gastroenterology"},{"issue":"8","key":"991_CR53","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/j.cgh.2021.11.012","volume":"20","author":"JE Ollech","year":"2022","unstructured":"Ollech JE, Bannon L, Maharshak N, et al. Fecal calprotectin is increased in pouchitis and progressively increases with more severe endoscopic and histologic disease. Clin Gastroenterol Hepatol. 2022;20(8):1839-1846.e2. https:\/\/doi.org\/10.1016\/j.cgh.2021.11.012.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"991_CR54","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/ajg.2015.129","volume":"110","author":"T Yamamoto","year":"2015","unstructured":"Yamamoto T, Shimoyama T, Bamba T, Matsumoto K. Consecutive monitoring of fecal calprotectin and lactoferrin for the early diagnosis and prediction of pouchitis after restorative proctocolectomy for ulcerative colitis. Am J Gastroenterol. 2015;110(6):881\u20137. https:\/\/doi.org\/10.1038\/ajg.2015.129.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"991_CR55","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/ecco-jcc\/jjab125","volume":"16","author":"ZS Ardalan","year":"2022","unstructured":"Ardalan ZS, Friedman AB, Con D, et al. Accuracy of gastrointestinal ultrasound and calprotectin in the assessment of inflammation and its location in patients with an ileoanal pouch. J Crohns Colitis. 2022;16(1):79\u201390. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab125.","journal-title":"J Crohns Colitis"},{"issue":"10","key":"991_CR56","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/ibd\/izaa191","volume":"26","author":"B Jagannath","year":"2020","unstructured":"Jagannath B, Lin KC, Pali M, Sankhala D, Muthukumar S, Prasad S. A Sweat-based Wearable Enabling Technology for Real-time Monitoring of IL-1\u03b2 and CRP as Potential Markers for Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020;26(10):1533\u201342. https:\/\/doi.org\/10.1093\/ibd\/izaa191.","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"991_CR57","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.cgh.2017.06.007","volume":"15","author":"A Heida","year":"2017","unstructured":"Heida A, Knol M, Kobold AM, Bootsman J, Dijkstra G, van Rheenen PF. Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity. Clin Gastroenterol Hepatol. 2017;15(11):1742-1749.e2. https:\/\/doi.org\/10.1016\/j.cgh.2017.06.007.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"991_CR58","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1136\/gutjnl-2021-326451","volume":"72","author":"C Argmann","year":"2023","unstructured":"Argmann C, Hou R, Ungaro RC, et al. Biopsy and blood-based molecular biomarker of inflammation in IBD. Gut. 2023;72(7):1271\u201387. https:\/\/doi.org\/10.1136\/gutjnl-2021-326451.","journal-title":"Gut"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-00991-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-025-00991-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-00991-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:02:54Z","timestamp":1772578974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-025-00991-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["991"],"URL":"https:\/\/doi.org\/10.1007\/s11894-025-00991-7","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"2 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}